Martin Shkreli, former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs with his attorney Benjamin Brafman (L) after a hearing at U.S. Federal Court in Brooklyn, New York, U.S., April 26, 2017. REUTERS/Brendan McDermid
NEW YORK (Reuters) - Martin Shkreli, the pharmaceutical entrepreneur vilified as the "pharma bro" for raising the price of a life-saving drug by 5,000 percent, will go on trial on Monday for what U.S. prosecutors called a Ponzi-like scheme at his former hedge fund and a drug company he once ran.
Prosecutors have accused Shkreli of lying to investors in the hedge fund and siphoning millions of dollars in assets from biopharmaceutical company Retrophin Inc to repay them. He has pleaded not guilty.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
